pg_pro_header_scientific_highlights
Visit this page for coverage of ParaGard® from major meetings in the field of women's health. Below is a list of conferences at which ParaGard® was featured prominently, along with abstracts and downloadable PDFs of articles presented at these meetings.

Meeting:
The 55th Annual Clinical Meeting of The American College of Obstetricians and Gynecologists,
May 5-9, 2007, San Diego, CA

Article Title:
Intrauterine Devices: Contraception's Best Kept Secret?

Abstract/Excerpt:
Education and information can be powerful tools in altering a woman's perception and attitude toward intrauterine devices (IUDs). Studies show that IUDs continue to be one of the least-used contraceptive options for American women, but a survey from Pittsburgh, PA, suggests that lack of information about IUDs—not an inherent dislike or distrust of the method—is a major barrier to expanding use.

To download the full text of this article, click here.

Email Updates
To stay current via email on scientific news fill out the form below:
* Represents a required field

* First Name:
  Middle Name:
* Last Name:
  Suffix:
* Street Address:
  Street Address 2:
* City:
* State:
* Zip Code:
* Email Address:
* State License #:
* Practitioner's Specialty:
* Practitioner's Designation:
To opt-out please click here.

I understand that by completing this registration form, I am providing information that may be deemed personally identifiable information. I authorize Duramed Pharmaceuticals, Inc. to disclose my personally identifiable information to its affiliated companies and contractors, including Barr Laboratories, Inc. (collectively, "Affiliates and Contractors"), on a need-to-know basis for purposes of administering programs related to ParaGard®. I understand that Duramed and its Affiliates and Contractors value their customers' privacy. As such, Duramed and its Affiliates and Contractors will take reasonable and appropriate measures to protect the information provided on this form from inappropriate disclosure. However, I also understand that this authorization permits Duramed and its Affiliates and Contractors to share my personally identifiable information with other individuals/entities that may not be bound ethically or by any privacy laws and that, once in their possession, my information could be used or re-disclosed for any purpose.
I understand that I may revoke this authorization, in writing, at any time by clicking here, or mailing to: ParaGard® Marketing Team, 225 Summit Avenue, Montvale, NJ 07645.
I understand that only an electronic revocation will constitute an effective withdrawal of my authorization, and that any such revocation will not be effective with respect to disclosures made by Duramed or its Affiliates or Contractors prior to receipt of the revocation by Duramed.
I have read and agree to the ParaGard® Terms of Use and ParaGard® Privacy Policy.

ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.